STOCK TITAN

Bionano Genomics Inc - BNGO STOCK NEWS

Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.

Bionano Genomics Inc: Pioneering Genome Analysis Solutions

Company Overview: Bionano Genomics Inc (Nasdaq: BNGO) is a specialized life sciences instrumentation company that focuses on transforming genomic research using its advanced optical genome mapping (OGM) technologies. With a strong emphasis on ultra-sensitive structural variation detection, the company delivers innovative solutions that support researchers and clinicians in uncovering genomic insights that traditional sequencing methods often miss.

Advanced Technology and Core Offerings: At the heart of Bionano’s portfolio is its state-of-the-art OGM platform. This technology offers unparalleled precision, enabling detailed structural analysis of genomes through high-speed, high-throughput mapping. The company’s tools are designed to reveal complex chromosomal rearrangements and structural variations, facilitating more complete genome assemblies which are crucial in areas such as cancer biology, molecular pathology, and agricultural bioengineering. Alongside its instruments, Bionano provides consumables and a robust, platform-agnostic analytic software suite that streamlines the interpretation of genomic data.

Operational Excellence and Market Strategy

Bionano operates globally with significant market activity in the Americas, EMEA, and Asia Pacific. The company generates product revenue through direct sales of its OGM systems, nucleic acid purification devices, and integrated software solutions. This holistic business model is tailored to support a diverse clientele that includes academic research institutions, clinical laboratories, and biotechnological organizations. By focusing on both innovative technology and customer success, Bionano has strategically positioned itself within the competitive landscape of genome analysis and research instrumentation.

  • Innovative Optical Genome Mapping: Enables detection of ultra-specific structural variations, unlocking new levels of genomic insight.
  • Integrated Software Solutions: The company’s analytical software enhances data reliability and provides a platform-agnostic approach to genome analysis.
  • Comprehensive Workflow Integration: From sample preparation to data analysis, Bionano offers an end-to-end solution facilitating streamlined research operations.

Industry Relevance and Competitive Landscape

Bionano Genomics is at the forefront of bridging the gap between traditional cytogenetics and modern genomic technologies. Its focus on uncovering hidden genomic rearrangements places it in a unique niche within the life sciences sector. Researchers and clinicians benefit from its advanced mapping solutions that address the limitations of older techniques such as karyotyping and fluorescence in situ hybridization (FISH). By providing high-resolution and comprehensive genomic data, Bionano significantly aids in precision medicine, cancer research, and various applications across molecular pathology.

Commitment to Research and Development

Beyond its technological innovations, Bionano is deeply committed to R&D and supporting its global customer base. The company invests in collaborations and research integrations that further enhance its genome analysis capabilities. This commitment not only drives technological advancements but also helps in refining its products and services, ensuring that users receive industry-leading support and resources. Bionano's collaborative efforts have led to numerous scientific publications, bolstering its reputation as an authority in the field of genome biology.

  • Enhanced Genomic Precision: The ability to detect complex and cryptic variations in the genome offers researchers a more complete understanding of genetic structures.
  • Streamlined Analytical Workflows: The integration of hardware and software solutions minimizes the need for multi-step, sequential analyses, thereby saving time and increasing operational efficiency.
  • Industry-Informed Innovations: By continuously integrating feedback from clinical and research environments, Bionano ensures that its technologies remain at the cutting edge of genome analysis.

In summary, Bionano Genomics Inc has built a robust reputation through its commitment to advancing genome analysis. Its innovative OGM technology, coupled with comprehensive analytical tools, plays a critical role in addressing complex genomic challenges. The company’s dedication to customer success and rigorous research and development makes it a pivotal contributor to the ongoing evolution of genomic science, delivering evergreen solutions that enhance our understanding of genome biology.

Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announces its 2024 Symposium, a virtual event featuring OGM presentations by 27 customers worldwide. The event will showcase applications in cancer, cell and gene therapy, and constitutional genetic disease. Bionano will also unveil a new product to advance cytogenetics and structural variant analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
none
-
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) reported unaudited preliminary financial and commercial highlights for Q4 2023. Revenue expected to be $10.4-10.7 million, a 27-30% increase over Q4 2022. Installed base of OGM systems increased by 36%, and nanochannel array flowcells sold expected to increase by 67% over Q4 2022. Full year 2023 revenue expected to be $35.8-36.1 million, a 29-30% increase over 2022. Cash, cash equivalents, and available-for-sale securities as of December 31, 2023, were approximately $102.8 million. The company achieved all full-year 2023 ELEVATE milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.23%
Tags
-
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced the addition of optical genome mapping (OGM) to the International System for Human Cytogenomic Nomenclature (ISCN). The OGM nomenclature is set to be published in the 2024 ISCN guide, providing a universal naming convention for genetic variants detected by OGM. This move is expected to enhance clear communication in publications and consistency in databases for genetic laboratories, marking a significant milestone for OGM and researchers using the workflow to advance molecular cytogenetics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
none
Rhea-AI Summary
Bionano Laboratories (Nasdaq: BNGO) announced the publication of the first framework paper for the clinical adoption and implementation of the optical genome mapping (OGM) workflow for hematological malignancy applications. The framework was co-authored by an international consortium of 18 cancer researchers and is intended to help laboratories with the uniform adoption and implementation of an OGM workflow. It includes recommendations for laboratories planning to adopt OGM on topics such as assay development, clinical validation, implementation, algorithms for data interpretation, and strategies for efficient reporting. The framework paper outlines specific recommendations in three areas: validation, quality control, and analysis and interpretation of variants. Bionano Laboratories developed its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne, based on the process outlined in this publication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
none
-
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced significant upgrades to its VIA™ software, enhancing the sensitivity and specificity for structural variation (SV) detection from optical genome mapping (OGM) data, further advancing OGM’s leadership in variant detection. The latest analysis pipeline, Bionano Solve 3.8.1, also enables comprehensive visualization, interpretation, and reporting of SVs and CNVs from OGM data in constitutional genetic disease research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
none
-
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced the results of a prospective prenatal study comparing optical genome mapping (OGM) to a combined workflow of chromosomal microarray analysis (CMA) and karyotyping (KT). OGM detected pathogenic structural variants in 20.5% of samples, outperforming CMA and KT in sensitivity, specificity, and positive predictive value. The study also revealed OGM's ability to identify novel pathogenic structural variants missed by traditional methods, showcasing its potential in prenatal diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.57%
Tags
none
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a special issue of Cancers journal dedicated to the Company’s optical genome mapping (OGM) workflow. The issue features eight peer-reviewed publications, with three additional publications expected, covering the use of OGM in hematological malignancy research and demonstrating its potential to offer significant research insights. The guest editors describe the advantages OGM has over traditional cytogenetic methods and note that OGM offers benefits for laboratory adoption. The issue’s publications cover research indications including acute myeloid leukemia, chronic lymphocytic leukemia, myeloma, and myeloid cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.67%
Tags
none
-
Rhea-AI Summary
Bionano Laboratories (BNGO) announced the publication of a study covering the analytical validation of its laboratory developed test (LDT), OGM-Dx™ HemeOne, based on optical genome mapping (OGM) analysis of blood or bone marrow samples to detect structural variants in individuals with hematological malignancies. The study demonstrated 100% concordance with traditional methods, 100% specificity and sensitivity for detecting Tier 1 and Tier 2 variants, and identified additional pathogenic variants in 28% of cases. The OGM workflow also showed reproducible concordant performance of 96.4% across all sites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
-
Rhea-AI Summary
Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the American Society of Hematology (ASH) Annual Meeting and Exposition 2023 will feature a broad range of content covering optical genome mapping's (OGM) utility for research in myeloid cancer, hematological malignancy, leukemia, and blood disorders. Dr. Enze Liu will present findings from a study on the use of OGM to detect structural variants in multiple myeloma. The ASH conference will be held December 9-12, 2023, in San Diego, California and online.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
none
Rhea-AI Summary
Bionano Laboratories (BNGO) announced the largest peer-reviewed study on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD). The study showed that the OGM-based laboratory developed test (LDT) was 100% accurate and precise when compared to the prior standard, Southern blot analysis. OGM identified 56% of FSHD1 cases and detected mosaic alleles in 3% of samples. The overall diagnostic yield of OGM and NGS combined was 58%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none

FAQ

What is the current stock price of Bionano Genomics (BNGO)?

The current stock price of Bionano Genomics (BNGO) is $3.1 as of April 1, 2025.

What is the market cap of Bionano Genomics (BNGO)?

The market cap of Bionano Genomics (BNGO) is approximately 8.1M.

What is the primary focus of Bionano Genomics Inc?

Bionano Genomics focuses on developing advanced optical genome mapping technologies to support detailed analysis of structural variations in genomes.

How does the company generate its revenue?

The company generates revenue primarily through direct sales of its innovative instruments, consumables, and accompanying analytical software solutions.

Which industries benefit from Bionano's technologies?

Industries such as cancer research, molecular pathology, cytogenetics, and agricultural bioengineering benefit from Bionano's high-resolution genome analysis tools.

How does Bionano differentiate itself from traditional genomic analysis methods?

Bionano differentiates itself by offering ultra-sensitive optical genome mapping that detects structural variations often missed by traditional sequencing and cytogenetic techniques.

What regions does Bionano operate in?

Bionano operates globally, with significant market presence in the Americas, EMEA, and Asia Pacific.

Who are the typical customers of Bionano Genomics?

Its typical customers include academic research institutions, clinical laboratories, and biotechnology companies that require advanced genome analysis solutions.

Why is optical genome mapping important in genomic research?

Optical genome mapping provides a higher resolution view of genome structure, allowing scientists to detect subtle yet critical structural variations that traditional methods may overlook.

Does Bionano offer any software solutions with its hardware products?

Yes, Bionano offers a comprehensive, platform-agnostic analytical software solution that enhances data analysis, interpretation, and integration with other genomic technologies.
Bionano Genomics Inc

Nasdaq:BNGO

BNGO Rankings

BNGO Stock Data

8.12M
2.73M
0.11%
10.24%
18.54%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States
SAN DIEGO